Introduction
While many scientists dream of a bright future from their scientific findings regarding therapeutic products, only a few of them ever go all the way to reap from their inventions. According to the article, less than half of the preclinical products often make it through to testing on humans, with only about a third reaching marketing authorization. The paper aims to enlighten scientists about the facts regarding the different steps contained in therapeutic product development. The article focuses on helping new scientists to have a better gauge of the chances of their development of the product and to better distinguish between platforms that will boost their performance from those that will bring them down.

Transforming discoveries into therapeutic ideas.
The article claims that open-minded scientists should occasionally ask themselves whether their discovery will be valuable past the better perception of nature. Alternatively, however, the article advises those seeking commercial value from the discovery not to hide their motive from the public for too long. Seeking to secure intellectual safeguard before publishing can leave a discovery antiquated. Therefore, scientists are advised to properly understand the new concept and procedures before moving into practical application.

Assessment of market value of new therapeutic concept
The article deduces that translation of scientific and demographic information should not be the primary business of a scientist. Instead they should only play a subordinate role in determining the market value of any novel treatment for the particular condition of medical. The scientists’ roles primarily have one principle: such worth often correlates with the highest sales that can be achieved with the treatment.

Ensuring appropriate conditions for development of therapeutic products
The article asserts that ensuring appropriate laboratory, manufacture and test conditions are preconditions that will help develop new therapeutic products. It highly prioritizes consistent data collection and recording. The article further asserts that the foundation is the principle for Good Laboratory Practice; regulations published in the Cod of Federal Regulations. These principles have been known to have the power of the law and thus characterizes the lowest standard for any product inventor and tester to achieve.

Good laboratory practice
According to the regulation agency for medicines and healthcare products, Good Laboratory Practice (GMP) exemplifies a group of codes that provide a structure for planning laboratory experiments, before observing, documenting, broadcasting and archiving them. These studies are considered for data generation, by which risks and hazards can be analyzed for food additives, pharmaceuticals, agrochemicals and contaminants. According to the article, implementation and maintenance of GLP requires the cooperation between quality assurance and quality control.

Good manufacturing practice
From the article, Good manufacturing practice (GMP) helps in ensuring excellence of products, meaning that one should strictly follow GMP, at least from product candidate entry into formal development phase. GMP, however, is not considered to be a set of manufacturing instructions or binding prescriptions. Instead, it is a group of general values applicable to the manufacture of products. Basically, all international and national GMP rules depend on the manufacture of quality products. Therefore, the assertion is that maintaining the guiding doctrines of GMP in mind is a requirement for timely recognition of possible issues like up-scaling matters.

Good clinical practice
According to the article, all test on human are subject to guidelines of Good Clinical Practice (cGCP), which summarizes the rules on international quality given by the ICH. Moreover, the cGCP focusses on protecting the human rights of study subjects during clinical studies. The article asserts that one needs to support any preclinical or clinical study by a set of standard operation procedures in line with GLP, GCP and GMP. The minimum recommendation of SOPs related to a standard test system must adhere to conditions such as regulation of preparation of room, and conditions of environmental room.

Regulatory framework to develop and launch new therapeutic products
The law prohibits substance testing or procedures on vertebrate without official consent, making the use of any therapeutic products on vertebrates tightly controlled. Therefore, the commercialization of any novel therapeutic products solely relies on fruitful conclusion of a series of examinations. Consequently, the article advises that innovators need to first confirm in preclinical animal test that have been pre-approved to justify further tests.

Risk minimization
Therapeutic product development demands thorough risk minimization, owing to the vast regulations that could be problematic and the low general probability of success. Risk management can be transparent, iterative, dynamic and responsive to changes if conducted well. In risk assessment, the first step involves identifying potential hazards and their characterization, followed by analysis of consequences of particular hazard occurrences. In the resultant procedure of analyzing business impact, the effect of each given threat is determined. According to the article, the minimum requirement at prevention of hazards requires that ways of reducing each risk are identified.

Closing remarks
According to the author, inventing or designing a therapeutic product is primarily an intellectual challenge. The article acknowledges that developing a therapeutic product is mainly hard work, accompanied with high cost and huge risks. The author advises that before any scientist starts the work, they need to first think through each development and basically mistrusting optimistic scenarios. The author also recommends partnerships, saying that they are vital forte development of any therapeutic product. The one could include professional consultants, service providers and prospective market planners to assist with the development. The author, however, acknowledges that regardless of its related challenges and burdens, research and development of therapeutic products can both be technologically and scientifically exciting.